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Abstract
Background: Effective pharmacotherapies are available for smoking cessation but their efficacy is
established through randomised controlled trials where the medication is supplied direct to
subjects. In health care settings patient access to medicines is often less direct. The process for
obtaining supplies of nicotine replacement therapy (NRT) is relatively easy for smokers attending
National Health Service (NHS) Stop Smoking Services in the UK, whilst this is not necessarily the
case for those wishing to using prescription only medicines (e.g. bupropion and varenicline). This
study was a direct comparison of the short-term validated abstinence rates of NRT and bupropion
in a clinical setting.
Methods: Data were routinely collected from 2626 clients setting a quit date (82% of those
registering) with two London NHS Stop Smoking Services that offered behavioural support
combined with pharmacotherapy (NRT and bupropion).
Results: Contrary to what would be expected from multiple randomised controlled trials, the
CO-validated 3–4 week abstinence rate in clients using NRT was higher than for bupropion (42%
versus 34%, p = .003). This difference persisted even when controlling for smoking characteristics,
demographic variables and treatment variables 1.40 (95% CI = 1.08 – 1.83).
Conclusion: Given that the level of behavioural support received by clients on each medication
was identical, the most plausible explanation for the difference in effectiveness between NRT and
bupropion perhaps lies with how clients of the Stop Smoking Services obtained their medications.
Obtaining NRT was relatively easy for clients throughout the study period whilst this was not the
case for bupropion. This study suggests that implementation issues and/or self-selection may
influence the effectiveness of medications in health care, as opposed to research, settings.
Background
The efficacy of pharmacotherapies is established through
randomised controlled trials where the medication is sup-
plied direct to subjects. In health care settings patient
access to medicines is often less direct and this may influ-
ence compliance with, and effectiveness of, medications.
Both nicotine replacement therapy (NRT) and bupropion
(Zyban) are of proven efficacy in helping smokers to quit.
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The most recent Cochrane review of multiple randomised
controlled trials of NRT found that the overall odds ratio
for long-term (6-month) abstinence with NRT, irrespec-
tive of additional support, compared to placebo was 1.77
(95% confidence intervals: 1.66 – 1.88) [1]. A Cochrane
review of over thirty trials of bupropion established that
the odds ratio for achieving abstinence from smoking for
at least six months was 1.94 (95% confidence interval:
1.72 to 2.19) [2]. Analysis of the three head-to-head trials
of bupropion and NRT included in the second of these
reviews also revealed that bupropion is slightly more
effective in helping smokers to achieve long term absti-
nence from smoking: the overall odds ratio was 1.34
(95% confidence interval: 0.71 to 2.56) [3-5].
A UK Government white paper in 1998 established the
importance of the treatment of tobacco dependence and
laid out a strategy for a NHS (National Health Service)
Stop Smoking Service [6]. Funding to create and develop
these stop smoking services was made available to all
areas by 2000 and by the end of 2001 most were fully
operational [7]. Bupropion became available on NHS pre-
scription in June 2000; a supply of four to six weeks of
NRT was obtainable via a voucher scheme operated by
NHS Stop Smoking Services up until April 2001 when it
too became available as an NHS reimbursable drug treat-
ment for smoking cessation [8].
This paper details previously unreported prior medication
use of clients attending NHS Stop Smoking Services and
what medication clients' chose to use to aid their quit
attempt. Our data allows us to report on usage of different
NRT products, and of bupropion, and to consider the
effectiveness of these medications in assisting clients
achieve short term abstinence in a clinical as opposed to
research setting. The data also allows for a direct compar-
ison to be made between the effectiveness of these medi-
cations as the level of behavioural support received by
clients on each medication type is identical.
There is evidence that providing free NRT to smokers can
induce a large number to make a quit attempt [9]; and
that making obtaining NRT easier (by switching the med-
ication from prescription only to over the counter [OTC])
can result in increased use of NRT [10]. However, these
large population-based cohort studies do not reflect what
goes on in clinical practice and to our knowledge there are
no studies that have considered how different routes of
access to smoking cessation medications can influence
their effectiveness.
Methods
The research took place at two NHS Stop Smoking Serv-
ices covering, in total, five outer London boroughs (Mer-
ton, Sutton & Wandsworth; Redbridge and Waltham
Forest) with a combined population of about one mil-
lion. These boroughs represent a diverse mix of inner city
and suburban residential areas where the percentage of
people of working age claiming key social benefits is 10%
(Merton, Sutton & Wandsworth), 14% (Redbridge) and
18% (Waltham Forest); the average for London is 15%
[11]. In both of these distinct services, the treatment regi-
men comprised six weekly 1–2 hour clinic (group) or
community (one-to-one) support sessions over five or six
weeks. This 'withdrawal-oriented treatment' [12] is rec-
ommended in smoking cessation guidelines [13] and
combines behavioural support and pharmacotherapy
(NRT or bupropion). This regimen is described in more
detail elsewhere [14] but basically involves a pre-quit ses-
sion to inform clients of what treatment involves, includ-
ing deciding upon what medication they are going to use
to aid their quit attempt. Subsequent sessions inform cli-
ents about the nature of the tobacco withdrawal syn-
drome and provide advice on how to manage the
symptoms, ensure that clients have a sufficient supply of
medication and are using it properly and provide encour-
agement designed to bolster motivation to remain absti-
nent.
All NHS stop smoking services collect demographic data
on clients plus abstinence data for four weeks post-quit.
The services reported in this paper also routinely collected
additional data including: past quit attempts, prior medi-
cation use, indicated cautions and contraindications,
choice of medication, side effects of medication use and
dependence on smoking – Fagerström test for nicotine
dependence (FTND) [15]. Data were collected as part of
routine clinical practice and all clients gave written per-
mission for the data to be used for research purposes. For
service evaluations like this approval from Research Ethics
Committees (REC) is not required [16]. Advice was
sought on this from Wandsworth REC who concurred.
Baseline data were collected by questionnaire prior to or
on the first visit, generally one or two weeks before the
quit date. Abstinence data were then collected on the quit
date and weekly for four weeks post-quitting. Treatment
outcome was defined according to the UK department of
Health service monitoring guidance [17] which is consist-
ent with the Society for Research in Nicotine and Tobacco
guidelines [18]. This allows for a two week 'grace period'
before complete cessation is required; thus short term
abstinence is defined as self-reported abstinence two
weeks after the quit day for the final two weeks of attend-
ance at the service, with a record of an expired-air CO
reading of less than ten parts per million for these final
two sessions. Only 1.7% (n = 77) of cases of self-reported
abstinence were not verified by an expired-air CO reading
of less than ten parts per million. These self-reported quit-
ters who were not CO-validated, plus non-quitters (n =
291) and clients lost to follow up (n = 126) were all
classed as non-abstinent. Data were entered on computerBMC Public Health 2009, 9:28 http://www.biomedcentral.com/1471-2458/9/28
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in anonymised form and analysed using SPSS version
13.0 [19].
Analysis
Categorical and continuous data were analysed using chi-
squared tests and t-tests respectively by abstinence status.
A series of simple univariate logistic regression analyses
were conducted to look at the relationship between CO-
validated 3–4 week abstinence and gender, age, tobacco
dependence (FTND), marital status, presence of other
smokers in household, employment status, educational
achievement, eligibility for free prescriptions, service,
service type (clinic or community) and choice of medica-
tion (bupropion or NRT). A forward stepwise multiple
logistic regression analysis was then conducted predicting
short-term abstinence including those variables signifi-
cant to p < .05. A forward stepwise multiple logistic regres-
sion analysis was also conducted predicting short-term
abstinence comparing the different forms of NRT control-
ling for all the variables remaining in the previous forward
stepwise regression.
Of the 3,200 smokers who registered with the services
between January 2001 and December 2003, 2,626 (82%)
set a quit date and it is on these that data are reported.
Results
The vast majority (82%, 2034/2496) of clients attending
the NHS Stop Smoking Services had attempted to stop
smoking in the past; 27% of clients (698/2496) reported
having made a single previous attempt and 54% (1336/
2496) more than one attempt. The mean number of pre-
vious serious attempts to stop smoking was 2.2 (range 0–
39, SD = 2.4). The median longest number of weeks absti-
nent for these previous quit attempts was 8 weeks (range
0–780). Over half (56%, 1430/2543) of clients who set a
quit date were eligible for free prescriptions (e.g. were on
low incomes, elderly or suffered from chronic health con-
ditions); 44% (1113/2543) had to pay the then standard
charge of £6.20 (approximately $12.40 or €7.85) per
individual prescription item. Table 1 shows client charac-
teristics of the study sample, which are typical of smokers
attending for treatment in the UK [20,21], with a compar-
ison for those choosing NRT and those choosing bupro-
pion to aid their quit attempt.
Sixty-three percent (1634/2579) of clients reported hav-
ing used NRT before. Data on other previous medication
use by clients was not available from the community set-
ting of one service and so the following findings are from
a subset of 1,947 clients. Only 10% (195/1879) of clients
Table 1: client characteristics
Total sample1 (n = 2,626) NRT2 (n = 1810) Bupropion2 (n = 388)
% (n)/mean (sd)
Sex: Female 59% (1536) 59% (1062) 57% (220)
Age* 45 (13.8) 46 (14.1) 44 (12.7)
Ethnicity: White* 85% (2183) 85% (1503) 91% (339)
Married/living with partner 51% (1299) 51% (897) 53% (197)
Education >16 years of age** 41% (1015) 41% (687) 55% (163)
In paid employment*** 46 % (1172) 44% (767) 60% (222)
Age started smoking 16.7 (7.9) 16.7 (5.1) 17.3 (17.0)
No of cigarettes per day 21.4 (10.1) 21.4 (10.4) 22.2 (9.5)
Smoking hand-rolled 21% (517) 21% (366) 21% (78)
FTND 5.7 (2.2) 5.7 (2.2) 5.8 (2.1)
Use of medication for mental health problem*** 13% (103) 17% (79) 4% (8)
Difference between NRT and bupropion significant to *p < .01; **p < .05 and *** p < .001
1 Represents the number of smokers setting a quit date with the services within the study period
2 Combined these represent the number of clients for whom medication use is recorded (n = 2238), where totals do not correspond it is because 
of missing values.BMC Public Health 2009, 9:28 http://www.biomedcentral.com/1471-2458/9/28
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reported having used bupropion before. Prior use of the
patch was reported by 47% (880/1885) of clients, 33%
(626/1879) had tried gum, 12% (228/1876) the inhala-
tor, 6% (103/1876) the sublingual tablet and 2% (44/
1873) the nasal spray. Data on past use of the nicotine
lozenge were only collected by the community treatment
arm of one service; 4% (30/787) of clients reported hav-
ing used it.
Three-percent (52/1907) of clients were contra-indicated
for bupropion; 5% (91/1907) presented with a condition
under which it should be prescribed with extreme caution
and 12% (232/1904) with caution. At the end of their first
consultation all 2626 clients were asked which medica-
tion they were going to use: 15% (388/2238) chose to use
bupropion, 69% (1810/2238) NRT and for 17% (428/
2238) their decision was unrecorded. Eighty-three percent
(1175/1385) of clients who reported having used NRT
before chose to use it again for their current quit attempt
compared with 76% (605/779) of clients who had not
used NRT previously (χ2 = 17.8, p < .001). Similarly, 37%
(59/159) of clients who had used bupropion before chose
to use it for this quit attempt compared with 17% (233/
1373) who had not used this medication before (χ2 =
38.3, p < .001).
Nearly one quarter (222/989) of those in full time
employment chose to use bupropion compared with 13%
(151/1143) of those not in employment (i.e. unem-
ployed, retired, students and carers) (χ2 = 31.3, p <.001).
Likewise a larger percentage of those not eligible for free
prescriptions (23%, 215/930) chose bupropion com-
pared with 13% (156/1202) of those who were on low
incomes (χ2 = 37.5, p <.001). There was also a difference
in choice of medication according to ethnicity, 18% (339/
1842) of white clients chose bupropion compared with
11% (33/301) of non-white clients (χ2 = 9.98, p = 0.002).
There were also differences in who chose to use bupro-
pion according to which service clients attended (23%,
297/1309 [Service 1] v 10%, 91/889 [Service 2], χ2 = 56.5,
p < .001) and to whether they attended the clinic (group)
or community (one-to-one) arm (31%, 222/729 v 11%,
166/1469 respectively, χ2 = 122.9, p < .001). Data on the
presence of "serious reactions" for bupropion were col-
lected by the community (one-to-one) treatment arm of
both services on the quit date: 6% (12/202) of clients
reported their presence and were advised to discontinue
the medication.
Overall the CO-validated 3–4 week abstinence rate was
41% (865/2129); for clients using bupropion it was 34%
(129/377) and for those using NRT it was 42% (736/
1752) (χ2 = 7.81, p = .005). More dependent smokers, as
measured by the FTND, were less likely to be abstinent
over this period (t = 3.61, df = 2183, p < .001). There was
no difference in short-term abstinence rates according to
which service clients attended (p = .46); but CO-validated
3–4 week abstinence rates were higher for clients treated
in clinics (i.e. group treatment) (43%, 388/911) than
those treated in the community (i.e. individual treatment)
(38%, 626/1638) (χ2 = 4.67, p = .031).
Male clients were more likely than female clients to be
abstinent at weeks 3 and 4 (42%, 445/1054 and 38%,
569/1488 respectively; χ2 = 4.08, p = .043); as were older
clients (t = -6.16, df = 2492, p = < .001). Short term absti-
nence rates also differed according to whether clients were
married (44%, 557/1255), separated or divorced (35%,
152/431) or single (36%, 243/668) (χ2 = 19.02, p <
.0001). There were no differences in abstinence rates
according to whether clients were eligible for free prescrip-
tions or not (p = .06), whether they had made a prior quit
attempt p = .06), whether clients had made one or more
than one previous quit attempt (p = .14) or how long their
previous quit attempt had lasted (p = .55).
Forty four percent (54/123) of clients reporting using at
least 14 bupropion tablets (range 14–30) in the week
prior to their quit date (the minimum recommended)
were abstinent at 3–4 weeks compared with 32% (12/38)
of those using below this amount (range 1–13); however
this difference did not reach statistical significance (p =
.26). Table 2 shows the results of a series of simple univar-
iate logistic regression analyses conducted to look at the
relationship between CO-validated 3–4 week abstinence
and smoking characteristics and relevant demographic
data.
Table 3 shows the results of a forward stepwise multiple
logistic regression of the items that reached significance of
p < .05 in the simple univariate regressions, including
choice of medication (bupropion/NRT). Use of NRT pre-
dicted greater chances of quitting compared with use of
bupropion. The chances of achieving short term absti-
nence was also greater among older clients, male clients,
clients in a stable relationship and those attending clinic
services compared with community services. Greater lev-
els of dependence as measured by the FTND predicted
lower chances of achieving CO-validated 3–4 week absti-
nence.
Table 4 shows the percentage choosing different NRT
products amongst those clients making a quit attempt
using NRT and the short term abstinence rates of those
using NRT by NRT type. There were no significant differ-
ences in CO-validated 3–4 week abstinence rates accord-
ing to which type of NRT clients chose to use to help them
with their quit attempt (χ2 = 4.25, p = .51).
Table 5 shows the results of a forward stepwise multiple
logistic regression predicting short-term abstinence com-
paring the different forms of NRT controlling for all theBMC Public Health 2009, 9:28 http://www.biomedcentral.com/1471-2458/9/28
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variables in the previous forward stepwise multiple regres-
sion (see Table 3). None of the NRT types independently
predicted short-term abstinence when controlling for
other variables.
Data collected on amount of medication used after the
quit date were not particularly useful because of differing
requirements (e.g. one patch per day compared with 10–
15 pieces of gum), but also because generally only absti-
nent clients continued to attend week on week. However,
even among returning clients no use of medication was
increasingly reported as the time since the quit date
increased: 0.7% (8/1143) at week one post-quit, 1.9%
(19/1002) at week two, 3.5% (31/892) at week three and
5.1% (45/878) at week four.
A sub-group of 822 clients, from the clinic arm of Service
1, responded to a baseline question about whether they
Table 2: Simple regression analysis predicting short term abstinence from smoking characteristics and demographic data*
Odds Ratio P value
Gender (female/male) 1.18 .044
Age 1.02 <.001
Marital status (single, divorced or separated/married or with partner) 1.43 <.001
FTND .93 <.001
Other smokers in household (no/yes) .96 .78
Past serious quit attempt (no/yes) 1.22 .06
Employment (not in full time/in full time) 1.12 .19
Education (no qualifications/GCSE or above) 1.00 .98
Free prescriptions (not eligible/eligible) .86 .06
Stop Smoking Service (1/2) 1.06 .46
Service type (community/clinic) 1.20 .031
Medication choice (bupropion/NRT) 1.39 .005
* This table reports on a number of separate simple univariate regressions to determine the independent effect of variables upon short term 
abstinence.
Table 3: Forward stepwise regression predicting short term abstinence*
Odds ratio P value
Medication choice (bupropion/NRT) 1.40 .012
Gender (female/male) 1.30 .009
Age 1.02 <.001
Marital status (single, divorced or separated/married or with partner) 1.33 .003
FTND .94 .006
Service type (community/clinic) 1.36 .012
* This table presents the output from a forward stepwise multiple regression where all the variables reaching significance in the univariate analyses 
(Table 2) were included in the model.BMC Public Health 2009, 9:28 http://www.biomedcentral.com/1471-2458/9/28
Page 6 of 9
(page number not for citation purposes)
were currently taking medication for a mental health
problem; 12.5% (103/822) reported using such medica-
tion. Ninety one percent (79/87) chose to use NRT and
9% (8/89) bupropion. The overall short-term quit rate for
clients currently taking medications for mental health
problems was 34%; 37% for those using NRT and 25% for
bupropion (χ2 = 0.5, p = .41).
Discussion
We might have expected bupropion to be more effective
than NRT, as the clinical trials suggested, but we found the
opposite. Also, bupropion was used more by clients who
were white, in employment, not eligible for free prescrip-
tions and who attended clinics as opposed to community
advisers. Although some NRT products produced better
short-term cessation rates than others these differences
were not reflected in the logistic regression. Previous seri-
ous quit attempts, irrespective of whether they were the
only prior quit attempt or how long they lasted, did not
result in lower cessation rates.
Obtaining NRT was relatively easy for clients throughout
the study period. In the first year, clients wanting to use
NRT were given a voucher at their first appointment (one
or two weeks prior to their quit date) for a free supply of
their chosen product, redeemable at their local commu-
nity pharmacy, which they could use on their quit date. In
the second year when NRT was available on prescription
clients were given a letter which recommended a GP pre-
scription of their chosen product; both services reported
that in most cases the client did not need to see the GP but
only to pick up the prescription from the surgery. Whereas
NRT is commenced on the quit date, bupropion has to be
taken 8–14 days prior to the quit date, allowing time for a
steady state concentration to be reached [22]. A letter was
issued from the Stop Smoking Services requesting that the
GP consider a prescription of bupropion, the client would
then need to book and attend an appointment and start
taking the medication at least a week prior to the quit
date. Clearly where the first appointment was only one
week prior to the quit date this would be impossible; even
when such an appointment was two weeks prior to the
quit date fulfilling this obligation would be a tall order. In
many cases it is likely that bupropion was not taken 8–14
days prior to the quit date, a counter-intuitive regimen
that may itself have contributed to sub-optimal adher-
ence, and one can only surmise at the implications of this
for the effectiveness of the medication. Additionally,
bupropion was only recommended for prescription 'with
behavioural support' [23] and the protocol for both serv-
ices was for patients approaching GPs for a prescription to
be directed to the Stop Smoking Service. The services
would conduct an assessment of suitability for bupropion
and then send the client back to the GP with a letter rec-
ommending bupropion. Continued prescriptions for
bupropion would be dependent not only on abstinence,
but on attendance at the Stop Smoking Service. It is plau-
sible that smokers wishing to quit with the aid of bupro-
Table 4: Choice of NRT medication by product and short-term abstinence rates by type of NRT used; % (n)
Product All clients (n = 1810) NRT type 3–4 week CO-validated abstinence (n = 502)
Inhalator 10.2 (185) Inhalator 37.2 (67)
16 hour patch 19.4 (352) Patch 43.0 (535)
24 hour patch 51.7 (936)
2 mg gum 1.5 (27) Gum 35.3 (30)
4 mg gum 3.3 (59)
Nasal spray 2.5 (46) Nasal spray 38.6 (17)
1 mg lozenge1 .1 (2) Lozenge 42.7 (44)
2 mg lozenge1 1.3 (23)
4 mg lozenge1 1.4 (25)
Lozenge2 3.0 (55)
Microtab 5.5 (99) Microtab 44.3 (43)
1 Service one only collected data on strength of lozenge. 2 Second service lozenge dataBMC Public Health 2009, 9:28 http://www.biomedcentral.com/1471-2458/9/28
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pion alone were 'forced' into accepting behavioural
support from their local NHS Stop Smoking Service.
Indeed this was the intention of the licensing instructions,
but it is unclear what affect the delay in quitting in order
to obtain bupropion, and forced attendance at treatment
sessions, had upon the dynamics of individual quit
attempts.
It is unknown what effect the milieu of quit attempts has
upon the chances of achieving abstinence. This is espe-
cially true of clients included in this study who were using
bupropion, as they were doing so in an atmosphere where
there was uncertainty over the safety of the drug. A series
of newspaper articles published in February 2001 profiled
a number of deaths in smokers using bupropion [24] and
the story was picked up by other newspapers and by the
BBC. The number of people receiving prescriptions of
bupropion fell from 29% to 21.5% in the next two quar-
ters [25], the public enthusiasm for bupropion had sud-
denly changed [26] and it is possible that this had some
impact upon how bupropion was perceived and used by
clients in this study.
Additionally, subjects enrolled in clinical trials are differ-
ent from smokers attending clinical services [27]. At the
very least, research subjects are normally expected to:
smoke a minimum number of cigarettes per day (usually
10), be both physically and mentally healthy, be literate
and be under the age of 75. The level of behavioural sup-
port provided to subjects is also often relatively intensive
compared with routine clinical practice, and varies in
intensity between different clinical trials. Therefore, less is
known about the effectiveness of these medications in a
'real world' clinical setting. It is reassuring that a combina-
tion of behavioural support and use of NRT or bupropion
was effective for clients reporting mental health problems,
a group of patients usually excluded from clinical trials.
Clients who previously used NRT and bupropion were
more likely to choose the same medication again for this
current quit attempt. Interestingly, a serious quit attempt
in the past did not result in lower cessation rates; neither
did whether they had made one or more than one attempt
or how long this previous attempt had lasted. Reported
gum use was high for prior use but significantly lower for
medication chosen for current quit attempt. This most
probably reflects that previous NRT use involved OTC
purchases.
As has been found previously, attendance at clinics
improved client's chances of quitting successfully com-
pared with attending community advisors for treatment.
[14]. The client group included in this study was fairly typ-
ical of those attending NHS services [20,21]: there was a
Table 5: Forward stepwise regression analysis between medication choice, smoking characteristics and demographic data and short 
term abstinence*
Odds ratio P value
Inhalator -. 2 3
Patch -. 3 2
Gum -. 4 7
Nasal spray -. 6 5
Lozenge -. 9 3
Microtab -. 6 0
Gender (male/female) 1.39 .003
Age 1.02 <.001
Marital status (single, divorced or separated/married or with partner) 1.33 .009
FTND .95 .03
Service type (community/clinic) 1.46 .002
* This table presents the output from a forward stepwise multiple regression where variables reaching significance in the univariate analysis (Table 
3) were included in the model alongside choice of NRT product. All of the NRT variables did not make it into the final model.BMC Public Health 2009, 9:28 http://www.biomedcentral.com/1471-2458/9/28
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significant percentage not in full time employment, the
majority were eligible for free prescriptions and mean
FTND score was relatively high. The data are limited by
the fact that this was a sample of relatively heavy smokers
attending treatment to help them stop, but this sample is
important in its own right. Data collected on medication
usage proved not to be reliable and was unable to be
meaningfully analysed; this should be a consideration for
similar future studies. There was also a large number of
'missing values' for many items; this may be typical of
data collected as part of routine clinical practice but
should be addressed in future research, possibly through
staff education. A further limitation of this paper is that it
reports on end of treatment (four week) abstinence from
smoking. However, the relapse rates for these clients after
four weeks of abstinence would be expected to be similar
to those described in a review of long term relapse curves
[28] and we can deduce from this that the likely long term
effect of treatment type is clinically important.
Conclusion
The level of behavioural support received by clients on
each medication was identical; therefore the most plausi-
ble explanation for the difference in effectiveness between
NRT and bupropion appears to lie with the ease with
which clients of the Stop Smoking Services obtained NRT
as opposed to bupropion. The role that press reports on
the safety of bupropion had upon the attitude of those cli-
ents taking it towards the medication and their quit
attempt is unknown.
The labile nature of human motivation and the tendency
towards relapse for those who are dependent upon
tobacco suggests that, once engaged in a quit attempt,
access to smoking cessation medications should be made
as easy as possible. This is especially relevant now with the
recent introduction of varenicline. Recent adverse press
reports on the safety of varenicline [e.g. [29,30]] draw fur-
ther parallels with bupropion and health professionals
involved in smoking cessation may need to be prepared to
answer queries from the public on such matters.
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